MYAM
NBIX icon

Meiji Yasuda Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Meiji Yasuda Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$895K Hold
5,312
– – 0.04% 289
2026
Q1 		$700K Buy
5,312
+27
+0.5% +$3.58K 0.03% 298
2025
Q4 		$750K Sell
5,285
-94
-2% -$13.6K 0.04% 279
2025
Q3 		$755K Sell
5,379
-414
-7% -$56.1K 0.04% 282
2025
Q2 		$728K Sell
5,793
-1,099
-16% -$126K 0.04% 286
2025
Q1 		$762K Sell
6,892
-368
-5% -$46.6K 0.03% 352
2024
Q4 		$991K Hold
7,260
– – 0.04% 312
2024
Q3 		$836K Sell
7,260
-24
-0.3% -$3.29K 0.03% 337
2024
Q2 		$1M Buy
7,284
+976
+15% +$134K 0.04% 306
2024
Q1 		$870K Sell
6,308
-2,732
-30% -$373K 0.04% 318
2023
Q4 		$1.19M Buy
9,040
+1,120
+14% +$129K 0.05% 292
2023
Q3 		$891K Buy
7,920
+4,980
+169% +$524K 0.04% 341
2023
Q2 		$277K Buy
2,940
+580
+25% +$56.7K 0.01% 522
2023
Q1 		$239K Sell
2,360
-3,930
-62% -$409K 0.01% 540
2022
Q4 		$751 Hold
6,290
– – 0.04% 359
2022
Q3 		$668K Sell
6,290
-140
-2% -$14.2K 0.04% 371
2022
Q2 		$627K Buy
6,430
+120
+2% +$11.1K 0.04% 401
2022
Q1 		$592K Sell
6,310
-120
-2% -$10.2K 0.03% 422
2021
Q4 		$548K Buy
+6,430
New +$591K 0.03% 372
2021
Q2 		– Sell
-4,900
Closed -$477K – 520
2021
Q1 		$477K Buy
4,900
+410
+9% +$43K 0.04% 354
2020
Q4 		$430K Buy
+4,490
New +$434K 0.04% 286

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Meiji Yasuda Asset Management's NBIX Position: Q2 2026 in Review

Meiji Yasuda Asset Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 5,312 shares worth $895K. The position accounts for 0.04% of the portfolio, ranked #289.

Meiji Yasuda Asset Management first reported a position in NBIX in Q4 2020 and has held it in 21 quarters since. The position peaked at $1.19M in Q4 2023. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Meiji Yasuda Asset Management held 5,312 shares of Neurocrine Biosciences worth $895K as of Q2 2026.
  • Meiji Yasuda Asset Management left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.04% of Meiji Yasuda Asset Management's portfolio in Q2 2026, its #289 holding.
  • Meiji Yasuda Asset Management first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 21 quarters since.
  • Meiji Yasuda Asset Management's Neurocrine Biosciences position peaked at $1.19M in Q4 2023.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Meiji Yasuda Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.